0
Skip to Content
Home
FAQ
FAQ
Report problems to the FDA
Report deceptive advertising
Watch & Learn
Browse All
A Patient's Story
DrB's Educational Presentations
Non-Preserved Eye Drop Safety
Regener-Eyes
StimulEyes
Sludge ™
The Placebo Effect
FDA Compliance
On Label, Off Label or No Label?
Placentas from Strangers
History
DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)
FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)
FDA Warning Letter to Neobiosis (June 5, 2024)
FDA Inspection Form 483 - RPP Tampa (June 23, 2023)
FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)
DEF Open Letter to the FDA (May 12, 2023)
DEF Open Letter to the Eye Care Press (May 5, 2023)
DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)
FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)
DEF Open Letter re StimulEyes (Mar 9, 2023)
DEF Open Letter to Regener-Eyes (Mar 5, 2023)
FDA Untitled Letter re StimulEyes (Nov 17, 2022)
FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)
DEF Open Letter to Regener-Eyes (Sep 29, 2022)
DEF Regulatory Compliance Summary Information (June 8, 2022)
DEF Open letter for Eye Care Professionals (May 16, 2022)
Open Menu
Close Menu
Home
FAQ
FAQ
Report problems to the FDA
Report deceptive advertising
Watch & Learn
Browse All
A Patient's Story
DrB's Educational Presentations
Non-Preserved Eye Drop Safety
Regener-Eyes
StimulEyes
Sludge ™
The Placebo Effect
FDA Compliance
On Label, Off Label or No Label?
Placentas from Strangers
History
DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)
FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)
FDA Warning Letter to Neobiosis (June 5, 2024)
FDA Inspection Form 483 - RPP Tampa (June 23, 2023)
FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)
DEF Open Letter to the FDA (May 12, 2023)
DEF Open Letter to the Eye Care Press (May 5, 2023)
DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)
FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)
DEF Open Letter re StimulEyes (Mar 9, 2023)
DEF Open Letter to Regener-Eyes (Mar 5, 2023)
FDA Untitled Letter re StimulEyes (Nov 17, 2022)
FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)
DEF Open Letter to Regener-Eyes (Sep 29, 2022)
DEF Regulatory Compliance Summary Information (June 8, 2022)
DEF Open letter for Eye Care Professionals (May 16, 2022)
Open Menu
Close Menu
Home
Folder:
FAQ
Back
FAQ
Report problems to the FDA
Report deceptive advertising
Folder:
Watch & Learn
Back
Browse All
A Patient's Story
DrB's Educational Presentations
Non-Preserved Eye Drop Safety
Regener-Eyes
StimulEyes
Sludge ™
The Placebo Effect
FDA Compliance
On Label, Off Label or No Label?
Placentas from Strangers
Folder:
History
Back
DEF Open Letter to Key Opinion Leaders (Nov 7, 2024)
FDA Warning Letter to Regenerative Processing Plant (Aug 16, 2024)
FDA Warning Letter to Neobiosis (June 5, 2024)
FDA Inspection Form 483 - RPP Tampa (June 23, 2023)
FDA Inspection Form 483 - RPP Palm Harbor (June 30, 2023)
DEF Open Letter to the FDA (May 12, 2023)
DEF Open Letter to the Eye Care Press (May 5, 2023)
DEF Open Letter to ABB Optical and Dry Eye Rescue (May 1, 2023)
FDA Public Safety Notification on Amniotic Fluid Eyedrops (Apr 10, 2023)
DEF Open Letter re StimulEyes (Mar 9, 2023)
DEF Open Letter to Regener-Eyes (Mar 5, 2023)
FDA Untitled Letter re StimulEyes (Nov 17, 2022)
FDA Untitled Letter to Regener-Eyes (Oct 5, 2022)
DEF Open Letter to Regener-Eyes (Sep 29, 2022)
DEF Regulatory Compliance Summary Information (June 8, 2022)
DEF Open letter for Eye Care Professionals (May 16, 2022)
Celebrity endorsement
regenereyes.com/chrisevert/
